Logo

Evidence of Hepatitis D Virus Infection in HBsAg Positive Subjects of Mashhad, North-East of Iran

Author(s):
Hosain NomaneeHosain Nomanee1, Sina RostamiSina Rostami2, Mohammad Taghi ShakeriMohammad Taghi Shakeri3, Zahra MeshkatZahra MeshkatZahra Meshkat ORCID1,*
1Antimicrobial Resistance Research Center, Mashhad University of Medical Sciences, Mashhad, IR Iran
2Department of Biology, Faculty of Sciences, Ferdowsi University of Mashhad, Mashhad, IR Iran
3Department of Biostatistics, Public Health School, Mashhad University of Medical Sciences, Mashhad, IR Iran


Jundishapur Journal of Microbiology:Vol. 8, issue 10; e7214
Published online:Oct 20, 2015
Article type:Letter
Received:Jul 11, 2012
Accepted:Sep 29, 2012
How to Cite:Hosain NomaneeSina RostamiMohammad Taghi ShakeriZahra MeshkatEvidence of Hepatitis D Virus Infection in HBsAg Positive Subjects of Mashhad, North-East of Iran.Jundishapur J Microbiol.2015;8(10):e7214.https://doi.org/10.5812/jjm.7214.

Dear Editor,

Anti-Hepatitis D Virus (HDV) among hepatitis B virus surface antigen (HBsAg) positive subjects has been reported from various countries such as Romania (1), Russia (2), Bangladesh (3), Pakistan (4), Saudi Arabia (5), Italy (6), and Mexico (7) with a prevalence of 83.3%, 12.5%, 24.4%, 16.6%, 8.6%, 8.3%, and 4%, respectively. According to studies carried out in Iran, HDV does not have a similar prevalence in different parts of the country. While the overall prevalence seems to have declined in Iran, studies demonstrated an upward trend of HDV infection prevalence among HBsAg-positive patients (8). As described previously, of 3198 individuals enrolled in this study, 34 were HBsAg positive (9). None of HBsAg-positive subjects were positive for anti-HDV.

Similar studies have been carried out in different parts of Iran and different prevalence rates have been reported. A study in Tehran, reported that HDV prevalence rate among Hepatitis B Virus (HBV) infected patients was 12.6% (10). Yaghob et al. observed HDV positivity in 2.2% of HBsAg blood donors in Shahrekord, West of Iran (11). In Golestan province, the prevalence was reported to be 5.8% (12). One study even noted a prevalence of 10.7% in Kerman (13), which is among one of the highest prevalence rates in Iran. In Tehran, capital of Iran, Rezvan et al. (14) noted anti-HDV Ab in 2.4% of HBsAg positive blood donors. According to previous studies in Iran, risk factors for becoming infected with HDV includes surgery, dentistry interventions, endoscopy, tattooing, war injury, traditional phlebotomy (Hejamat), and family history (15).

In our study, none of the HBsAg-positive subjects had positive results for anti-HDV. Since vaccination against HBV can also protect against HDV infection, the data of this study confirms the notion that expanded HBV vaccination coverage in our region might limit the spread of HDV in the normal population. Since HDV infection among HBV carriers could not be prevented unless by educating individuals to prevent further exposures, preventive measures such as vaccination against HBV is necessary but not sufficient for decreasing the prevalence (16). Further investigations with larger sample sizes seem essential to clarify risk factors and prevalence rates in our region.

Acknowledgments

Footnotes

References

  • 1.
    Tapalaga D, Forzani B, Hele C, Paravacini O, Ponzetto A, Theilmann L. Prevalence of the hepatitis delta virus in Rumania. Hepatogastroenterology. 1986;33(6):238-9. [PubMed ID: 3804180].
  • 2.
    Ivaniushina VA, Ryzhova EV, Grudinin MP, Katorgina LG, Nikonova AN, Vinogradova EN, et al. [The frequency of antibodies against delta virus in patients with HBs positive hepatitis]. Vopr Virusol. 1996;41(4):166-9. [PubMed ID: 8999671].
  • 3.
    Zaki H, Darmstadt GL, Baten A, Ahsan CR, Saha SK. Seroepidemiology of hepatitis B and delta virus infections in Bangladesh. J Trop Pediatr. 2003;49(6):371-4. [PubMed ID: 14725415].
  • 4.
    Mumtaz K, Hamid SS, Adil S, Afaq A, Islam M, Abid S, et al. Epidemiology and clinical pattern of hepatitis delta virus infection in Pakistan. J Gastroenterol Hepatol. 2005;20(10):1503-7. [PubMed ID: 16174065]. https://doi.org/10.1111/j.1440-1746.2005.03857.x.
  • 5.
    Al-Traif I, Ali A, Dafalla M, Al-Tamimi W, Qassem L. Prevalence of hepatitis delta antibody among HBsAG carriers in Saudi Arabia. Ann Saudi Med. 2004;24(5):343-4. [PubMed ID: 15573844].
  • 6.
    Gaeta GB, Stroffolini T, Chiaramonte M, Ascione T, Stornaiuolo G, Lobello S, et al. Chronic hepatitis D: a vanishing Disease? An Italian multicenter study. Hepatology. 2000;32(4 Pt 1):824-7. [PubMed ID: 11003629]. https://doi.org/10.1053/jhep.2000.17711.
  • 7.
    Munoz Espinosa LE, Ibarra Salas MJ. [Prevalence of hepatitis D in a population of Northeast Mexico and its relationship with other viruses]. Rev Gastroenterol Mex. 1997;62(4):246-9. [PubMed ID: 9580232].
  • 8.
    Shahinsaz L, Sabahi F, Karimi M, Behzadian F, Alavian SM, Zand V. Detection and genotyping of hepatitis D virus from HBsAg positive patients in Iran using RT-PCR. Iran J Biotech. 2006;4(3):174-9.
  • 9.
    Shakeri MT, Foghanian B, Nomani H, Ghayour-Mobarhan M, Nabavinia MS, Rostami S, et al. The prevalence of hepatitis B virus infection in Mashhad, Iran: a population-based study. Red Crescent Med J. 2013;15(3):245-8.
  • 10.
    Foroutan H, Nemati A, Nasiri-Tosi M, Ghofrani H, Keivani H. Prevalence of hepatitis delta virus infection in various groups with HBVinfection in Tehran, Imam Khomeini Hospital (2005-2006). Med J Islam Repub Iran. 2008;22(2):93-7.
  • 11.
    Yaghob R, Momeni M, Tajbakhsh F, Hamedi S. Serological survey of HDV-Ab in HBsAg positive blood donors in Shahrekord, Iran. Afr J Microbiol. 2011;5(10):1243-5.
  • 12.
    Roshandel G, Semnani S, Abdolahi N, Keshtkar AA, Besharat S, Joshaghani H, et al. Prevalence of hepatitis D virus infection in HBsAg positive subjects in Iran. Pak J Biol Sci. 2007;10(10):1751-4. [PubMed ID: 19086531].
  • 13.
    Zahedi M, Darvish-Moghaddam S, Zareei H. Clinical Impact and Frequency of Hepatitis D Virus Infection in HBsAg Positive Patients in a Southern Province of Iran (Kerman). Iran J Virol. 2010;3(2):1-6.
  • 14.
    Rezvan H, Forouzandeh B, Taroyan S, Fadaiee S, Azordegan F. A study on delta virus infection and its clinical impact in Iran. Infection. 1990;18(1):26-8. [PubMed ID: 2155876].
  • 15.
    Alavian SM, Alavian SH. Hepatitis D virus infection; Iran, Middle East and Central Asia. Hepat Mon. 2005;5(4):137.
  • 16.
    Abbas Z, Jafri W, Raza S. Hepatitis D: Scenario in the Asia-Pacific region. World J Gastroenterol. 2010;16(5):554-62. [PubMed ID: 20128022].
comments

Leave a comment here


Crossmark
Crossmark
Checking
Share on
Metrics

Purchasing Reprints

  • Copyright Clearance Center (CCC) handles bulk orders for article reprints for Brieflands. To place an order for reprints, please click here (   https://www.copyright.com/landing/reprintsinquiryform/ ). Clicking this link will bring you to a CCC request form where you can provide the details of your order. Once complete, please click the ‘Submit Request’ button and CCC’s Reprints Services team will generate a quote for your review.
Search Relations

Author(s):

Related Articles